| Cat.No. | Name | Information |
|---|---|---|
| M14815 | HA Peptide TFA | HA Peptide (TFA) is a nine amino acids peptide derived from the human influenza hemagglutinin (HA). HA Peptide (TFA) is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry. |
| M14814 | HA Peptide | HA Peptide (HA tag) is a nine amino acids peptide derived from the human influenza hemagglutinin (HA). HA Peptide is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry. |
| M14812 | ADH-1 trifluoroacetate | ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion. |
| M14811 | Elabela(19-32) TFA | Elabela(19-32) TFA is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) TFA activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) TFA induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart. |
| M14810 | Elabela(19-32) | Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart. |
| M14807 | Cibinetide | Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for the research of neurological disease. |
| M14805 | Activated Protein C (390-404), human | Activated Protein C (390-404), human is a peptide of the activated protein C (a vitamin K-dependent serine protease), potently inhibits APC anticoagulant activity. |
| M14804 | Acetyl-PHF6 amide TFA | Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide. |
| M14802 | 3X FLAG peptide | 3X FLAG Peptide is a synthetic peptide with a 3-time repeated DYKXXD motif. |
| M14801 | 11R-VIVIT TFA | 11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy. |
| M14799 | Abaloparatide TFA | Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue selected to be a potent and selective activator of the PTHR1 signaling pathway. |
| M14795 | Z-Ala-Ala-Asn-AMC | Z-Ala-Ala-Asn-AMC (Cbz-Ala-Ala-Asn-AMC) is the legumain substrate. Overexpressed legumain in 293 HEK-Leg cells potently cleaved CBZ-Ala-Ala-Asn-AMC. |
| M14784 | Teriparatide | Teriparatide (Human parathyroid hormone-(1-34)) is a PHT agonist, with an IC50 of 2 nM in HEK293 cells. |
| M14537 | Bivalirudin TFA | Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin. |
| M14360 | Copper tripeptide | Copper tripeptide (GHK-Cu), a naturally occurring tripeptide, is first isolated from human plasma, but can be found in saliva and urine. |
| M14157 | D-JNKI-1 | D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK. |
| M14067 | Argipressin | Argipressin (Arg8-vasopressin) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1. |
| M14063 | Pasireotide acetate | Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). |
| M14062 | Octreotide | Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. |
| M13970 | Lixisenatide acetate | Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
